Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
argenx SE is a global immunology-focused biotechnology company specializing in the discovery, development, and commercialization of antibody-based therapies for severe autoimmune diseases and rare conditions. The company operates within the biopharmaceutical and biotechnology industries, with a strategic emphasis on translating antibody science into targeted treatments that address significant unmet medical needs.
The company’s core business is driven by the development and commercialization of therapies derived from its proprietary antibody engineering platforms, most notably its neonatal Fc receptor (FcRn) antagonism approach. argenx’s lead product, Vyvgart (efgartigimod), is approved for the treatment of generalized myasthenia gravis and represents the primary revenue driver. Founded in 2008 as a spin-out from academic research in antibody technologies, argenx has evolved from a research-centric organization into a fully integrated commercial-stage biotechnology company with global operations.
Business Operations
argenx operates through integrated research and development, clinical development, and commercial operations functions. The company generates revenue primarily from product sales of Vyvgart and Vyvgart Hytrulo, supported by internal discovery platforms that advance a pipeline of antibody-based therapeutics across multiple autoimmune indications.
Operations span both domestic and international markets, with clinical trials, regulatory activities, and commercialization conducted across North America, Europe, and Asia-Pacific. The company controls proprietary antibody engineering and FcRn biology technologies and collaborates with contract manufacturing organizations for large-scale biologics production. argenx maintains wholly owned subsidiaries in key jurisdictions to support clinical development, regulatory compliance, and commercial distribution.
Strategic Position & Investments
argenx’s strategy centers on establishing leadership in FcRn antagonism and expanding its immunology franchise through lifecycle management of efgartigimod and pipeline diversification. Growth initiatives include expanding approved indications for Vyvgart, developing next-generation formulations, and advancing earlier-stage assets targeting complement-mediated and antibody-driven diseases.
The company has made significant long-term investments in clinical programs and manufacturing readiness rather than large-scale acquisitions. Its pipeline includes both wholly owned programs and assets originating from its proprietary SIMPLE Antibody™ platform. argenx continues to invest in emerging immunology technologies and late-stage clinical development to support sustained revenue growth and market expansion.
Geographic Footprint
argenx is headquartered in The Netherlands, with dual operational headquarters in Belgium and the United States. The company maintains a strong presence in North America and Europe, which represent its largest commercial and clinical markets, and has expanded operations into Japan and other parts of Asia-Pacific to support regulatory approvals and commercialization.
Its global footprint includes research facilities, regional commercial organizations, and clinical trial sites across multiple continents. International investment and operational influence are primarily focused on markets with advanced regulatory frameworks for biologics and significant prevalence of autoimmune diseases.
Leadership & Governance
argenx is led by an executive team with extensive experience in biotechnology, immunology, and global pharmaceutical commercialization. The leadership emphasizes a science-driven culture, disciplined clinical execution, and long-term value creation through innovation in antibody therapeutics.
Key executives include:
- Tim Van Hauwermeiren – Chief Executive Officer
- Ian Clark – Chief Financial Officer
- Luc Truyen, MD, PhD – Chief Medical Officer
- Nicolas Prévot – Chief Operating Officer
- Hans de Haan, PhD – Chief Scientific Officer
The company operates under a governance framework consistent with European and U.S. public company standards, with strategic oversight focused on pipeline execution, regulatory success, and global commercial expansion.